Organization Overview
Alternative names
acetylsalicylic acid (aspirin) (2 trials)
autologous ebv specific cytotoxic t lymphocytes (1 trial)
bacille calmette-guerin (1 trial)
carboplatin (paraplatin) (7 trials)
docetaxel (taxotere) (3 trials)
epinephrine (levophed) (1 trial)
ethiodized oil (ethiodol) (1 trial)
fenofibrate (fenoglide) (1 trial)
fluorouracil (efudex) (6 trials)
gemcitabine (gemzar) (6 trials)
ad5f35-lmp1/lmp2-transduced autologous dendritic cells (1 trial)
allogeneic cik cells (1 trial)
anastrozole (arimidex) (1 trial)
antigen pulsed dendritic cells (1 trial)
atezolizumab (Tecentriq) (2 trials)
autologous epstein-barr virus-specific cytotoxic t lymphocytes (1 trial)
autologous microbiome (1 trial)
bevacizumab (avastin) (3 trials)
bortezomib (velcade) (1 trial)
cangrelor (kengreal) (1 trial)
capecitabine (xeloda) (7 trials)
cyclophosphamide (cytoxan) (5 trials)
dacomitinib (vizimpro) (2 trials)
doxorubicin (Doxil) (4 trials)
etoposide (vepesid) (2 trials)
exemestane (aromasin) (1 trial)
ibrutinib (imbruvica) (1 trial)
ipilimumab (yervoy) (2 trials)
irinotecan (Camptosar) (3 trials)
menaquinone (vitamin k2) (1 trial)
metronidazole (flagyl) (1 trial)
ofatumumab (arzerra) (1 trial)
osimertinib (tagrisso) (1 trial)
oxaliplatin (eloxatin) (9 trials)
pembrolizumab (keytruda) (4 trials)
Acute Coronary Syndrome (Phase 2)
Adenocarcinoma (Phase 1)
Antisocial Personality Disorder (Phase 3)
Autism Spectrum Disorder (Phase 4)
Autistic Disorder (Phase 4)
Body Weight (Phase 4)
Brain Diseases (Phase 1)
Brain Ischemia (Phase 1)
Breast Neoplasms (Phase 2)
Calcinosis (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 3)
Cardio-Renal Syndrome (Phase 3)
Cerebral Infarction (Phase 3)
Child Development Disorders, Pervasive (Phase 4)
Cognitive Dysfunction (Phase 4)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 3)
Dry Eye Syndromes (Phase 1)
Eczema (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fatigue (Phase 2)
Hand-Foot Syndrome (Phase 3)
Head and Neck Neoplasms (Phase 3)
Heart Arrest (Phase 3)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Hematologic Neoplasms (Phase 2)
Hemorrhage (Phase 4)
Hepatitis (Phase 4)
Hepatitis A (Phase 4)
Hepatitis B (Phase 4)
Hepatitis B, Chronic (Phase 4)
Hepatitis, Chronic (Phase 4)
Hernia (Phase 3)
Hernia, Inguinal (Phase 3)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 2)
Hypertension (Phase 1)
Hypoxia (Phase 1)
Hypoxia-Ischemia, Brain (Phase 1)
Infarction (Phase 3)
Influenza, Human (Phase 4)
Insulin Resistance (Phase 4)
Ischemia (Phase 1)
Keratoconjunctivitis Sicca (Phase 1)
Kidney Diseases (Phase 3)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 2)
Liver Neoplasms (Phase 3)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1)
Melanoma (Phase 1)
Meningeal Neoplasms (Phase 1)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myopia (Phase 3)
Nasopharyngeal Carcinoma (Phase 3)
Nausea (Phase 3)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neoplasms, Squamous Cell (Phase 2)
Neurodevelopmental Disorders (Phase 3)
Obesity (Phase 2)
Ovarian Neoplasms (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Postoperative Nausea and Vomiting (Phase 3)
Postpartum Hemorrhage (Phase 4)
Reperfusion Injury (Phase 2)
Rhinitis (Phase 2)
Rhinitis, Allergic (Phase 2)
Sarcoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 2)
Stroke (Phase 4)
Syndrome (Phase 3)
Urinary Bladder Neoplasms (Phase 3)
Vascular Calcification (Phase 2)
Ventricular Remodeling (Phase 3)
Vitamin D Deficiency (Phase 4)
Vitamin K Deficiency (Phase 2)
Vomiting (Phase 3)
Weight Gain (Phase 4)
Weight Loss (Phase 4)